GastroenterologyustekinumabCrohn's disease
Ustekinumab Shows Short-Term Benefit for Fistulising Perianal Crohn's Disease in Small Randomized Trial
By MedXY|Jul 26, 2026
A randomized trial found ustekinumab significantly improved combined clinical and radiological remission at week 12 vs placebo in fistulising perianal Crohn's disease, though long-term outcomes were less clear.